Compare Inovio Pharmaceuticals Inc (INO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Match Group Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Match Group Inc trades at $38.9 (market cap $9.10B). The key difference: Match Group Inc is far larger — about 101.9× Inovio Pharmaceuticals Inc's market cap, and Match Group Inc pays a 2.05% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MTCH | |
|---|---|---|
Market Cap | $89.27M | $9.10B |
Sector | Health | Media |
52-Week High | $2.87 | $40.29 |
52-Week Low | $1.05 | $28.90 |
Enterprise Value | $60.28M | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MTCH trades at $39.10, down 0.13% today, with a bullish technical outlook supported by moving averages and key resistance at $40. The company reported Q1 2026 revenue growth of 4% but missed EPS expectations. Strong profitability is evident with a 73.8% gross margin and 17.59% net margin. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The stock presents a moderate buy opportunity with a consensus price target of $41.63, offering ~6% upside. Risks include Tinder's user declines and high debt levels, but valuation multiples like a P/E of 14.94 suggest potential undervaluation. Investor sentiment is positive, with no analyst sell ratings, though execution on user growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
